At the beginning of the meeting Paolo conmented that he was very aware of the pps decline and that he was disappointed that ARQL hadn't delivered greater value to shareholders. He could not offer any explanation for it.
It was a very positive event. It appears the management - knows what they are doing - expects a good HCC presentation at this year ASCO - was able to complete on time the enrollment of the PhIII NSCLC trial in spite of a competition for NSCLC patients from other companies - expects to file for the targeted NSCLC indication sometime late in 2013 - feels good about PhI results for a mutated-melanoma indication
The ASCO 2012 is next.
PS Marty, sorry to miss you at the meeting. At the end, everybody left very fast.